Category - Developments

Developments

Ekso Bionics launches virtual eksoUniversity to support CE for PTs and PTAs

Ekso Bionics (NASDAQ: EKSO) has announced the launch of eksoUniversity, a new platform providing continuing education (CE) courses to physical therapists (PTs) and physical therapy assistants (PTAs) across the U.S. Most...

July 18, 2025

Developments

Cognition’s positive data from Phase 2 study of zervimesine in DLB presented at AAIC

Cognition Therapeutics (NASDAQ: CGTX) has announced that James Edward Galvin, MD, MPH, will present results from the Phase 2 SHIMMER study of zervimesine (CT1812) in dementia with Lewy bodies (DLB) during an oral...

July 17, 2025

Developments

Revelation completes patient dosing in study of Gemini in CKC

Revelation Biosciences (NASDAQ: REVB) has announced the completion of dosing for its PRIME Phase 1b study of escalating doses of intravenously administered Gemini—a proprietary formulation of phosphorylated hexaacyl...

July 17, 2025

Developments

Cell One Partners’ video series: Dr. Stephen Chang reflects on 40 years of innovation in cell and gene therapy

In the latest episode of consulting company Cell One Partners’ video series—Cell One Insights—on cell and gene therapy, Stephen Chang, PhD—a human geneticist and partner at Cell One Partners—shares insights from his 40...

July 15, 2025

Developments

BiomX doses first patient in Phase 2b trial of BX004 in CF

BiomX (NYSE: PHGE) has announced the initiation of patient dosing in its Phase 2b trial evaluating BX004 for the treatment of cystic fibrosis (CF) patients with chronic pulmonary infections caused by Pseudomonas...

July 15, 2025

Developments

Firefly’s FDA-cleared BNA platform underpins groundbreaking precision neuroscience study with Heidelberg University

Firefly Neuroscience (NASDAQ: AIFF) has announced its continued collaboration with Prof. Christian Schaaf, MD, Director of the Institute of Human Genetics at Heidelberg University Hospital and Chairman of Human Genetics...

July 14, 2025

Developments

Oncogene publishes remission for testicular cancer patient treated with MiNK’s iNKT cell therapy

MiNK Therapeutics (NASDAQ: INKT) has highlighted a publication in the peer-reviewed journal Oncogene describing a complete and durable remission in a patient with metastatic, treatment refractory testicular cancer...

July 11, 2025

Developments

China’s NMPA approves Ascentage’s lisaftoclax for CLL/SLL

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) has announced that China’s National Medical Products Administration (NMPA) has approved its proprietary novel Bcl-2 selective inhibitor lisaftoclax (APG-2575) for the...

July 10, 2025

Developments

PharmaJet enters MOU for needle-free vaccine delivery in Egypt

Closely held PharmaJet has announced the signing of a Memorandum of Understanding (MOU) with the Egyptian Unified Procurement Authority (UPA) and closely held EVA Pharma. The agreement aims to explore the integration of...

July 10, 2025

Developments

Cogent reports positive topline results from SUMMIT trial of bezuclastinib in NonAdvSM

Cogent Biosciences (NASDAQ: COGT) has announced positive topline results from the SUMMIT trial of bezuclastinib in patients with non-advanced systemic mastocytosis (NonAdvSM), achieving statistical significance across...

July 7, 2025

Category - Developments

Subscribe